Actinium Pharmaceuticals Receives Sell Rating Upgrade Amid Market Movements

On November 11th, 2023, Actinium Pharmaceuticals NYSEAMERICAN:ATNM received a significant update to its stock rating. Investment research firm StockNews.com elevated the company's rating from 'strong sell' to 'sell'. This shift reflects a nuanced change in the perception of Actinium Pharmaceuticals' prospects within the investment community.

Analyst Insights on Actinium Pharmaceuticals

Prior to the upgrade, varied opinions from several other brokerage firms about Actinium Pharmaceuticals circulated. B. Riley maintained a 'buy' rating with a price target of $20.00, showing optimism about the company's potential. Similarly, HC Wainwright reaffirmed a 'buy' rating with an ambitious price target of $50.00. Additionally, HSBC initiated coverage assigning a 'buy' rating and a target price of $11.60 to the company. Despite the latest 'sell' rating from StockNews.com, the overall consensus from different analysts pegged Actinium Pharmaceuticals with a 'Hold' rating and an average target price of $27.15.

Actinium Pharmaceuticals Stock Price Movement

The stock opened at $4.41 on the day preceding the announcement of the upgrade, showcasing a noticeable decline of 5.6%. This price sits within a range having a 1-year low of $4.31 and a peak at $14.70. Additionally, the stock has been balancing around a 50-day simple moving average of $9.53 and reports a market capitalization of $120.88 million, with a P/E ratio standing at -2.44 and a beta of 0.31.

In terms of financials, Actinium Pharmaceuticals' latest quarterly earnings report was on August 14th, where the biotechnology firm recorded a loss of ($0.58) earnings per share (EPS), falling short of the consensus estimate by ($0.08). Analysts anticipate that the company might post an EPS of -2.03 for the current fiscal year.

Institutional Interest in Actinium Pharmaceuticals

Institutional investors and hedge funds have shown interest in Actinium Pharmaceuticals, with some adjustments to their holdings. Notably, UBS Group AG UBS, with its expertise in providing financial solutions globally, increased its stake in the company by 76.2%, signaling a vote of confidence. Their new aggregate of shares amounted to a valuation of about $34,000. Other entities such as Quent Capital LLC, Royal Bank of Canada RBCPF, California State Teachers Retirement System, and The Manufacturers Life Insurance Company also made notable investments during the same timeline.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. focuses on the development of targeted radiotherapies aimed at treating patients with severe medical needs. The lead product candidate, I-131 apamistamab (Iomab-B), is currently in a pivotal Phase III clinical trial intended for bone marrow transplant conditioning in elderly patients with acute myeloid leukemia. There is also an ongoing Phase I study exploring a CD19-targeted CAR T-cell therapy at the Memorial Sloan Kettering Cancer Center.

Actinium, Pharmaceuticals, Investment